KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Cash & Equivalents data on record, last reported at $5.1 billion in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 11.27% year-over-year to $5.1 billion; the TTM value through Dec 2025 reached $5.1 billion, up 11.27%, while the annual FY2025 figure was $5.1 billion, 11.27% up from the prior year.
  • Cash & Equivalents reached $5.1 billion in Q4 2025 per VRTX's latest filing, up from $4.9 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $11.1 billion in Q3 2023 and bottomed at $4.6 billion in Q4 2024.
  • Average Cash & Equivalents over 5 years is $7.6 billion, with a median of $7.2 billion recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 75.44% in 2021, then plummeted 55.93% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $6.8 billion in 2021, then surged by 54.47% to $10.5 billion in 2022, then decreased by 1.28% to $10.4 billion in 2023, then tumbled by 55.93% to $4.6 billion in 2024, then rose by 11.27% to $5.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $5.1 billion in Q4 2025, $4.9 billion in Q3 2025, and $4.6 billion in Q4 2024.